Journal
CURRENT RHEUMATOLOGY REPORTS
Volume 15, Issue 2, Pages -Publisher
SPRINGER
DOI: 10.1007/s11926-012-0304-0
Keywords
PDGF; Scleroderma; Fibrosis; Mouse model; Animal models; Pericyte; Imatinib; Neutralizing antibody; Therapeutic
Categories
Funding
- NIGMS NIH HHS [P20 GM103636] Funding Source: Medline
Ask authors/readers for more resources
Fibrosis is the principal characteristic of the autoimmune disease known as scleroderma or systemic sclerosis (SSc). Studies published within the last three years suggest central involvement of platelet-derived growth factors (PDGFs) in SSc-associated fibrosis. PDGFs may also be involved in SSc-associated autoimmunity and vasculopathy. The PDGF signaling pathway is well understood and PDGF receptors are expressed on collagen-secreting fibroblasts and on mesenchymal stem and/or progenitor cells that may affect SSc in profound and unexpected ways. Although much work remains before we fully understand how PDGFs are involved in SSc, there is much interest in using PDGF inhibitors as a therapeutic approach to SSc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available